Evidence map›Paper›PMID 31966855›Full record

ArticleInternational journal of clinical and experimental pathology2017

Associations of LIM kinase1 (LIMK1) gene single nucleotide polymorphisms with prostate cancer susceptibility in Chinese population.

Wuran Wei, Guojun Zeng, Chang Liu, Bingwen Zou, Li Li

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Wuran WeiInstitute of Urology, Department of Urology, West China Hospital, Sichuan University Chengdu, China.
Guojun ZengDepartment of Vascular Surgery, West China Hospital, Sichuan University Chengdu, China.
Chang LiuDepartment of Liver Surgery, West China Hospital, Sichuan University Chengdu, China.
Bingwen ZouDepartment of Oncology, West China Hospital, Sichuan University Chengdu, China.
Li LiKey Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education Chengdu, China.
West China Second University Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer is one of the most common cancers in men. LIM kinase1 (LIMK1) is a mediator in the process of cytoskeleton reorganization and cell motility. LIMK1 is related to progression, invasiveness and metastases of prostate cancer. However, the relationship between LIMK1 single nucleotide polymorphism (SNP) and the risk of prostate cancer has not been studied.

aimThe aim of our study is to determine the association between LIMK1 polymorphisms and the risk of prostate in a Chinese population.

methodsThis case-control study consisted of 162 prostate cancer patients and 187 healthy control subjects. Five SNPs of LIMK1 including rs2269082, rs2269081, rs178409, rs6460071 and rs710968 were genotyped using iPLEX genotyping assays on a MassARRAY

resultsNo significant relationships were found between polymorphisms genotypes and the risk of prostate cancer. Also, no significant associations were found between genotypes and the individual factors such as Gleason Score, alcohol and cigarette consuming statuses.

conclusionThese polymorphisms of LIMK1 were not significantly associated with prostate cancer susceptibility in Chinese men.

Indexed as

cancer riskgene variantLIM kinase1 (LIMK1)Prostate cancersingle nucleotide polymorphism

Identifiers

PMID31966855
PMCPMC6965917
OpenAlexW3004439732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.